about
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch SystemDeregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.A Novel Serum 4-microRNA Signature for Lung Cancer Detection.Pemetrexed for the treatment of non-small cell lung cancer.Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.Role of microRNAs in malignant mesothelioma.Afatinib for the treatment of advanced non-small-cell lung cancer.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer.Oral vinorelbine in the treatment of non-small-cell lung cancer.Efficacy of motesanib diphosphate in non-small-cell lung cancer.Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.Belagenpumatucel-L for the treatment of non-small cell lung cancer.Classification of different patterns of pulmonary adenocarcinomas.Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report.Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma.
P50
Q27004790-562B4630-8327-49DC-8F14-A534D23B6DA5Q33784593-6465447A-7570-4AAE-B01C-A3D21CAA1AA2Q34165233-79874E9E-0B05-4AAD-8359-9DE46A57CC5DQ34762165-2C6A318B-7575-4314-BC2E-0605254FF9B3Q36117926-385D0785-B386-4BA0-97EF-447DEF42AB16Q36404083-327FF7A5-A724-4554-82D8-65B09052E982Q37736206-F8D58644-77F5-4951-932F-819F1CF06068Q38107552-937CBA0D-77A0-430B-8157-EACDE4E7F8A9Q38170384-AB9CF216-8DEB-4731-B9B4-317AB89E5176Q38190418-8E65E5E1-BD5C-40D8-90B2-B4C1857AB71FQ38197278-F98144FA-E214-4C8E-950A-DB780B485951Q38202161-E6AF7A5B-D814-4D7F-B7DC-8C8CD5B4E43EQ38220103-B24C02FB-026D-4B87-B2D3-0DE1C38ED0C7Q38223910-296D3AAF-F1F1-4F51-821C-B4CCB17858A9Q38230556-C2274581-1FF2-429F-A2C0-E4AE879FC15DQ38286303-AFB288BD-B192-4F43-95CA-467D7BB3C3F0Q38554476-A197B327-E754-43D7-B6EA-F5E775CFB21CQ38574971-09FCB1F3-3DDE-4231-9FE8-2B768D746350Q38862340-41019399-D5E0-4915-A5D1-9F62DCEBAEFEQ38945524-A0D036D9-0EA1-4D5E-97BE-B91A2FB11382Q40206402-9E26703F-21A8-4AD7-B261-E3613DDD148EQ42152754-1A91677D-AA08-4E86-9601-7671C691E555Q47652834-5AF5E2BA-D4C5-4365-A07A-705F33530320Q52568478-29FF61FF-254A-4D69-9E29-4F19FE36F11DQ53841963-8C456987-864D-4DAD-98C4-70A64625C2A7
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anna Truini
@ast
Anna Truini
@en
Anna Truini
@es
Anna Truini
@nl
type
label
Anna Truini
@ast
Anna Truini
@en
Anna Truini
@es
Anna Truini
@nl
prefLabel
Anna Truini
@ast
Anna Truini
@en
Anna Truini
@es
Anna Truini
@nl
P108
P106
P108
P1153
55584615800
P21
P31
P496
0000-0002-4600-6497